TransEnterix Wins Life Sciences Company Award from NCTA
Research Triangle Park, NC, November 13, 2010 --(PR.com)-- For developing a new system that allows surgeons to operate entirely through a patient’s belly button, TransEnterix received the “Life Sciences Company” award Wednesday from the North Carolina Technology Association (NCTA).
The prestigious award was conferred Nov. 10 during the NCTA’s annual 21 Awards program, which was attended by more than 850 guests representing government and industry. This particular award honors a company that has achieved a milestone of innovation or other measurable success within the past year.
In TransEnterix’s case, NCTA recognized its successful launch of the SPIDER® Surgical System earlier this year. The SPIDER system resolves the challenges that surgeons encounter using first-generation belly button systems and completely changes the state of single-incision surgery.
“Conventional laparoscopic surgery worked well for 20 years, but for the field of minimally invasive surgery to progress, surgeons need better tools – and TransEnterix is dedicated to developing these tools,” said Todd M. Pope, president and CEO. “The SPIDER system offers improved access to the operating site, and provides surgeons the angles and equipment needed to successfully complete single-incision procedures. This has been a truly exciting year for our company, made more so by NCTA’s recognition of what we’ve accomplished.”
The SPIDER system’s ability to open up inside the abdomen and its flexible instruments are proprietary technologies created by TransEnterix; they are not available in any other single-incision system on the market. Since April, surgeons have used the SPIDER system to successfully treat obesity, colon cancer and hernias, and to remove kidneys and gallbladders. To see how it works, visit www.spidersurgery.com
About TransEnterix
TransEnterix partners with leading medical thought-leaders to rapidly develop pioneering technologies that advance minimally invasive surgery. Having received the appropriate regulatory clearance, TransEnterix is commercializing its operations and marketing the SPIDER Surgical System in the United States and Europe. Since its start in 2006, the company has secured $75 million in venture capital funding.
Note To Media: B-roll videotape, B-roll animation and high-resolution photos of the SPIDER system are available.
###
The prestigious award was conferred Nov. 10 during the NCTA’s annual 21 Awards program, which was attended by more than 850 guests representing government and industry. This particular award honors a company that has achieved a milestone of innovation or other measurable success within the past year.
In TransEnterix’s case, NCTA recognized its successful launch of the SPIDER® Surgical System earlier this year. The SPIDER system resolves the challenges that surgeons encounter using first-generation belly button systems and completely changes the state of single-incision surgery.
“Conventional laparoscopic surgery worked well for 20 years, but for the field of minimally invasive surgery to progress, surgeons need better tools – and TransEnterix is dedicated to developing these tools,” said Todd M. Pope, president and CEO. “The SPIDER system offers improved access to the operating site, and provides surgeons the angles and equipment needed to successfully complete single-incision procedures. This has been a truly exciting year for our company, made more so by NCTA’s recognition of what we’ve accomplished.”
The SPIDER system’s ability to open up inside the abdomen and its flexible instruments are proprietary technologies created by TransEnterix; they are not available in any other single-incision system on the market. Since April, surgeons have used the SPIDER system to successfully treat obesity, colon cancer and hernias, and to remove kidneys and gallbladders. To see how it works, visit www.spidersurgery.com
About TransEnterix
TransEnterix partners with leading medical thought-leaders to rapidly develop pioneering technologies that advance minimally invasive surgery. Having received the appropriate regulatory clearance, TransEnterix is commercializing its operations and marketing the SPIDER Surgical System in the United States and Europe. Since its start in 2006, the company has secured $75 million in venture capital funding.
Note To Media: B-roll videotape, B-roll animation and high-resolution photos of the SPIDER system are available.
###
Contact
TransEnterix
Karen Stinneford
919.833.9102
www.sinclair-co.com
Karen Stinneford
919.833.9102
www.sinclair-co.com
Contact
Categories